Applying for clinical trials for heart disease with iPS cells Osaka University research group October 23, 4:48
A research group at Osaka University would like to apply for an examination at a reviewing agency about the operation of applying the muscle cells of the heart made from iPS cells to the heart of a patient with severe heart disease. I understand. Insurance is expected that the establishment of a common treatment to be applied earlier, we aim to implementation of the first case of surgery to prospect in the current fiscal year.
The research group of Prof. Yoshiki Sawa of Osaka University restores the function by making a sheet of heart muscle cells made from iPS cells that form various body tissues and pasting them directly onto the heart of patients with severe heart disease. I am studying treatments aimed at
The group applied to the Osaka University Screening Board and was approved by the 23rd of the month to conduct surgery using the “myocardial sheet” as a clinical trial aimed at commercialization as soon as possible. In response to this, the group will apply to the national review body for clinical trials this month.
This treatment method was initially approved by the national review as a clinical study, and preparations have been made, but the group conducted surgery as a clinical trial based on the technology for cultivating cells that were advanced later, and safety and The fact that we decided to confirm the effectiveness is expected to be established as a general treatment to which insurance is applied.
Surgery for heart disease therapy using iPS cells is the first time in the world, we want to perform the surgery of the first case of a patient in prospect in the current fiscal year as long recognized the applicant.
What is the current status of iPS regenerative medicine application?
IPS cells developed by Prof. Shinya Yamanaka of Kyoto University are being clinically applied to regenerative medicine that restores the lost function of the body at universities throughout Japan.
Five years ago, for the first time in the world, teams such as RIKEN in Kobe City targeted a serious eye disease called “age-related macular degeneration” and transplanted the eye retina tissue made from iPS cells. Currently, safety and effects are being evaluated.
In November of last year, a group of Kyoto University performed an operation to transplant cells made from iPS cells into the brains of patients with Parkinson's disease, an intractable disease that caused their bodies to move. The group has started clinical research aimed at restoring vision by transplanting corneal tissue made from iPS cells into patients.
In addition, there are clinical studies that have been completed for national review and are being prepared for implementation. Another group at Kyoto University will conduct clinical research to administer platelets made from iPS cells to patients with blood disorders.
In addition, Keio University group is planning clinical research aiming at recovery of function by transplanting nerve cells made from iPS cells to patients whose spinal cords were damaged due to accidents etc. and became unable to move.